We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.65 | 4.52 | 4.99 | - | 189,060 | 10:52:51 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.36M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 31/7/2020 15:57 | Hammer that finish. | howmanyfools | |
| 31/7/2020 15:04 | wetdream it goes on if you go to the original doc. Do believe SNG has measured all suggested endpoints and as reported to date, have met them all. | waterloo01 | |
| 31/7/2020 15:00 | waterloo01, The wording here could have been written by Synairgen! ‘For outpatients with mild COVID-19, regulators agreed that mortality as the primary endpoint may not be suitable. Instead, the rate of progression to severe disease and the proportion of patients not hospitalised at a pre-specified time point may be more appropriate, depending on the primary objective of the study.‘ | wetdream | |
| 31/7/2020 14:50 | Nice one and we seemingly tick the boxes. | tickboo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
